Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective Evaluation of Nivolumab in First-Line Unresectable Advanced or Metastatic Gastric Cancer (GC) and Gastroesophageal Junction Cancer (GEJC): A Non-interventional Observational Study in China

NCT06452329 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT06452329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06452329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective Evaluation of Nivolumab in First-Line Unresectable Advanced or Metastatic Gastric Cancer (GC) and Gastroesophageal Junction Cancer (GEJC): A Non-interventional Observational Study in China
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
February 28, 2024
Completion date
July 29, 2025
Enrollment
260 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastroesophageal junction cancer